Original articleFrequency and type of reactions to antituberculosis drugs: Observations in routine treatment
References (18)
A review of blood dyscrasias induced by the antituberculosis drugs
Tubercle
(1987)- et al.
Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis
Tubercle Lung Dis
(1994) Adverse effects of antituberculosis drugs
Drugs
(1982)Adverse cutaneous reactions to antituberculosis drugs
Int J Dermatol
(1985)The ocular toxicity of ethambutol and its relation to dose
Ann NY Acad Sci
(1966)- et al.
Adverse effects of antituberculosis drugs causing changes in treatment
Tubercle
(1982) - et al.
6-months isoniazid and rifampin therapy for pulmonary tuberculosis: report of a USPHS Cooperative trial
Am Rev Respir Dis
(1984) A controlled trial of 6-months chemotherapy in pulmonary tuberculosis: First report: results during chemotherapy
Br J Dis Chest
(1981)Management and outcome of pulmonary tuberculosis in adults notified in England and Wales in 1983
Thorax
(1988)
There are more references available in the full text version of this article.
Cited by (127)
Transient Transfection of the Respiratory Epithelium with Gamma Interferon for Host-Directed Therapy in Pulmonary Tuberculosis
2020, Molecular Therapy Nucleic AcidsHow to Manage a Patient on Anti-TB Therapy with Abnormal Liver Enzymes
2017, Infectious Diseases, 2-Volume SetNovel risk factors and early detection of anti tubercular treatment induced liver injury—Looking beyond American Thoracic Society Guidelines
2017, Indian Journal of TuberculosisCitation Excerpt :Another aspect of DILI is that it decreases treatment effectiveness, because it significantly contributes to noncompliance, ultimately contributing to treatment failure, relapse or the emergence of drug-resistance. Understanding of ATT-related DILI has been hampered by differences in study populations, definitions of hepatotoxicity, monitoring, and reporting practices.6–9 Literature reveals that rate of DILI during standard multidrug treatment range from 2.3% to 28% world over.10
Antituberculosis drug-induced non-blistering systemic severe reactions: A 10-year (2012-2022) literature review
2023, Asian Pacific Journal of Allergy and ImmunologyRisk Management Assessments of Anti-tuberculosis Adverse Drug Reaction: A Systematic Review
2021, E3S Web of ConferencesEffects of co-administration of unani pharmacopoeia formulations qurs tabasheer sartani and arq hara bhara with cat-i antitubercular drugs in rats
2021, Journal of Complementary and Integrative Medicine
Copyright © 1996 Published by Elsevier Ltd.